Sinopharm wants to give 6m vaccine doses to Bangladesh
Published: 04:12 PM, 17 April 2021 Updated: 04:14 PM, 17 April 2021
At a time when coronavirus (Covid-19) infections and deaths are on the rise in the country, Chinese pharmaceutical company Sinopharm has offered 6 million doses of the vaccine.
According to the relevant sources, the pharmaceutical company has been proposed to give 6 million doses of vaccine to Bangladesh a few days ago through a credible source.
About this, Health Minister Zahid Maleque told the media that China’s Sinopharm has proposed to give 6 million doses of COVID BBIBP-CorV vaccine to Bangladesh through a credible source.
“We are emphasizing this issue. Negotiations are underway,” he said, adding, “We can move towards buying vaccines from China only if Sinopharm provided us relevant information.”
It is to be mentioned that China’s Beijing Institute of Biological Products developed an inactivated coronavirus vaccine called BBIBP-CorV in early 2020.
Meanwhile, several other countries around the world, including China, the United Arab Emirates (UAE), Bahrain, Egypt and Pakistan, are using the vaccine.
On December 30 last year, Sinopharm said that the effectiveness of their vaccine was 79.34 percent. The Chinese government then approved the use of the vaccine. The UAE approved the use of the Sinopharm vaccine in early December. Citing the interim results of the third phase of the trial, they said “the vaccine had an 86 percent effectiveness.”
Besides, the Bangladesh government is contacting Russia for the Sputnik V vaccine. Russia approved the Sputnik V vaccine for use inside the country in August 2020.
Asked about the Russian vaccine update, the Health Minister said the Bangladeshi ambassador had spoken to Russian authorities about it. Negotiations are ongoing.
Meanwhile, the Bangladesh government has signed an agreement to buy 30 million doses of vaccine from the Seram Institute of India. Till yesterday, 7 million doses of vaccine were received in two phases.
However, to meet its domestic demand, India has temporarily banned the export of the AstraZeneca vaccine made by the Serum Institute.